|
|
|
| Dec. 29, 2003 |
Amgen Named One of Fortune Magazine's '100 Best Companies to Work For'
|
| Dec. 15, 2003 |
Amgen Forecasts Strong 2004 Financial Performance
|
| Dec. 9, 2003 |
Amgen Names David Beier Senior Vice President, Global Government Affairs
|
| Dec. 9, 2003 |
Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources
|
| Dec. 7, 2003 |
Analysis of Head-to-Head Studies Shows That Aranesp(R) Dosed Every Two Weeks Offers Similar Results With Less Frequent Administration Compared to Epoetin Alfa
|
| Dec. 6, 2003 |
New Data Suggest Aranesp(R) Benefits Patients Suffering From Anemia of Cancer, Who Are Not Receiving Chemotherapy
|
| Dec. 1, 2003 |
Amgen Announces Webcast of Conference Call to Provide Financial Guidance for 2004
|
| Nov. 16, 2003 |
Aranesp(R) Administered Once Monthly Maintains Hemoglobin Levels in Patients With Chronic Kidney Disease
|
| Nov. 15, 2003 |
Cinacalcet HCl Phase 3 Results Demonstrate Improvement in the Management of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
|
| Nov. 11, 2003 |
Amgen Announces Plans for Epratuzumab
|
| Oct. 24, 2003 |
Long-Term Data Support Sustained Efficacy, Tolerability and Increased Vitality For Psoriatic Arthritis Patients Treated With ENBREL and Landmark Phase 3 Data Show Ankylosing Spondylitis Patients Experienced Partial Clinical Remission, Improved Pain Relief
|
| Oct. 24, 2003 |
New Data Show Many Rheumatoid Arthritis Patients Treated With ENBREL Plus Methotrexate Have Experienced Clinical Remission and Most Had No Progression of Joint Damage
|
| Oct. 23, 2003 |
Science Recognizes Amgen as a Top Employer in Annual Survey
|
| Oct. 21, 2003 |
Amgen's Third Quarter 2003 Adjusted Earnings Per Share Increases 56% to 53 Cents
|
| Oct. 20, 2003 |
FDA Approves ENBREL for Once-Weekly Dosing
|
| Oct. 16, 2003 |
Amgen Names H. Christian Fibiger, Ph.D., and Paul G. Pearson, Ph.D., As Vice Presidents to Lead Research Efforts
|
| Oct. 14, 2003 |
Abgenix and Amgen Clarify Responsibilities for ABX-EGF
|
| Oct. 6, 2003 |
Amgen Announces Webcast of Third Quarter 2003 Financial Results
|
| Sep. 8, 2003 |
Amgen Submitted New Drug Applicatioin for Cinacalcet HCI
|
| Sep. 8, 2003 |
Amgen and Biovitrum Sign License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders
|
| Sep. 3, 2003 |
Amgen Foundation Gives $8 Million in Grants in 2002
|
| Aug. 27, 2003 |
AMGEN AND GENENTECH SETTLE PATENT DISPUTE
|
| Aug. 25, 2003 |
FDA APPROVES ENBREL AS FIRST THERAPY TO INHIBIT BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS
|
| Jul. 31, 2003 |
FDA Approves Enbrel(R) as Treatment to Improve Physical Function in Rheumatoid Arthritis Patients
|
| Jul. 24, 2003 |
Enbrel is First Biologic to Receive FDA Approval for the Treatment of Ankylosing Spondylitis
|
| Jul. 9, 2003 |
TEN THOUSAND PATIENTS ENROLLED IN LANDMARK RHEUMATOID ARTHRITIS STUDY PROGRAM
|
| Jul. 8, 2003 |
Amgen Names Dr. Willard Dere Vice President, Global Inflammation Clinical Development
|
| Jul. 8, 2003 |
Enbrel is First Anti-TNF Therapy Submitted to the FDA for Approval to Treat Psoriasis
|
| Jul. 1, 2003 |
Amgen Announces Webcast of Second Quarter 2003
|
| Jun. 24, 2003 |
Enbrel is First Biologic Recommended by FDA Panel for Approval to Treat Ankylosing Spondylitis
|
| Jun. 20, 2003 |
Enbrel Combination Therapy Inhibited Progression of Joint Damage and Offered Significant Rheumatoid Arthritis Symptom Relief in New Clinical Study
|
| Jun. 19, 2003 |
In a New Clinical Study, Enbrel Taken Once Weekly Significantly Reduced Pain and Inflammation and Improved Function in Rheumatoid Arthritis Patients
|
| Jun. 19, 2003 |
Enbrel Rapidly and Significantly Improved Back Pain, Mobility and Physical Function in Patients with Ankylosing Spondylitis
|
| Jun. 19, 2003 |
Enbrel Provided Rapid and Significant Relief for Psoriasis Patients in Second Pivotal Study
|
| Jun. 16, 2003 |
New Study Demonstrates Combination Therapy with Enbrel Inhibited Progression of Joint Damage and Offered Significant Symptom Relief for Rheumatoid Arthritis Patients
|
| Jun. 16, 2003 |
New Data Highlight Aranesp Efficacy in Anemic Patients with Lymphoid Cancer
|
| Jun. 10, 2003 |
Amgen Announces First Annual Recipient of the Amgen Prize for Therapeutic Advances in Nephrology
|
| Jun. 2, 2003 |
New Data Suggest Risk of Infection Doubles with Reduced NEUPOGEN Administration
|
| Jun. 1, 2003 |
Aranesp Dosed Once Every Two Weeks Increases Hemoglobin Levels, Improves Fatigue And Reduces Need For Transfusions In Patients With Chemotherapy-Induced Anemia
|
| Jun. 1, 2003 |
Phase 3 Data Suggest Palifermin Significantly Reduces the Duration and Incidence of Oral Mucositis in Cancer Patients
|
| May. 31, 2003 |
Amgen Launches The Amgen Oncology Institute To Support Cancer Education
|
| May. 31, 2003 |
Interim Phase 2 Data Demonstrate Single-Agent Antitumor Activity With ABX-EGF In Advanced Colorectal Cancer
|
| May. 28, 2003 |
Deborah Norville Launches National Hope Relay in Celebration of People Leading Active Lives Despite their Rheumatoid Arthritis
|
| May. 21, 2003 |
Amgen Appoints Industry Veteran Dr. David R. parkinson To Head oncology Clinical Development
|
| May. 5, 2003 |
2003 Seattle-Area Recipients of Amgen Award for Science Teaching Excellence Announced
|
| May. 5, 2003 |
2003 Rhode Island Recipients of Amgen Award for Science Teaching Excellence Announced
|
| May. 5, 2003 |
2003 Puerto Rico Recipients of Amgen Award for Science Teaching Excellence Announced
|
| May. 5, 2003 |
2003 Jefferson County Recipients of Amgen Award for Science Teaching Excellence Announced
|
| May. 5, 2003 |
2003 Colorado Recipients of Amgen Award for Science Teaching Excellence Announced
|
| May. 5, 2003 |
2003 California Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 4, 2003 |
Amgen Announces Webcast of First Quarter 2003 Financial Results
|
| Mar. 20, 2003 |
Amgen Announces $800 Million Investment In Juncos, Puerto Rico For Biotech Manufacturing Center
|
| Mar. 3, 2003 |
Rob Lowe Launches Town Meetings To Help Cancer Patients And Their Loved Ones Understand Chemotherapy And its Side Effects
|
| Feb. 25, 2003 |
Amgen Provides Business Overview Through 2005
|
| Feb. 19, 2003 |
Amgen Announces Webcast Of Business Review Meeting
|
| Jan. 27, 2003 |
J&J Ordered To Pay Amgen's Costs and Attorneys' Fees In Recent Arbitration
|
| Jan. 24, 2003 |
Amgen Announces Award for Science Teaching Excellence in King and Snohomish Counties
|
| Jan. 23, 2003 |
On an Adjusted Basis, Amgen Reports Fourth Quarter Earnings Per Share Increase 17 Percent to 35 Cents, Full Year 2002 Increase 18 Percent to $1.39
|
| Jan. 23, 2003 |
Amgen and Immunomedics Announce Emphasis On Development Of AMG 412 (Epratuzumab) As Combination Therapy While Closing Single Agent Trial
|
| Jan. 23, 2003 |
Amgen Announces Positive Results Of Phase 3 Study For rHu-KGF
|
| Jan. 17, 2003 |
Amgen Announces Positive Results of Phase 3 Enbrel Study in Psoriasis
|
| Jan. 15, 2003 |
Amgen Announces Webcast Of Fourth Quarter And Full Year 2002 Financial Results
|
| Jan. 6, 2003 |
Federal Appeals Court Affirms TKT Infringement; Remands Certain Validity Issues to Lower Court
|
| Jan. 2, 2003 |
Epogen - Important Prescribing Information
|
